Madrigal Pharmaceuticals Reveals Inducement Award Grants in Compliance with Nasdaq Listing Rule 5635(c)(4)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 04 2025
0mins
Source: Globenewswire
Equity Awards Granted: Madrigal Pharmaceuticals announced the granting of equity awards to 17 new non-executive employees as part of its 2025 Inducement Plan, totaling 4,510 time-based restricted stock units, which will vest over four years.
Focus on MASH Treatment: The company specializes in developing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), with its medication Rezdiffra being the first approved treatment for MASH with moderate to advanced fibrosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
